In accordance with the findings from molecular research, it has been reported that immunohistochemical staining of Plk1 in primary breast tumors was significantly associated with the presence of non-functional mutated p53, which predicted a significantly worse survival than those with either Plk1 expression or TP53 mutation alone [86]. This evidence concerns the gene TP53 and breast neoplasm.